Reaction

Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 179 reports · 6 co-occurring drugs

As of the last recalculation, Myocarditis-Myositis-Myasthenia Gravis Overlap Syndrome appears in 179 FAERS reports alongside 6 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 148.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Pembrolizumab	77	148.6	148.7
Durvalumab	16	100.3	100.4
Ipilimumab	29	93.0	93.1
Pemetrexed	15	88.7	88.8
Nivolumab	51	85.4	85.4
Pemetrexed Disodium	17	57.2	57.2

Related reactions

Drug Ineffective
Off Label Use
Death
Nausea
Fatigue

Data source: openFDA FAERS. See the OpenPV methodology and limitations.